|
Kiniksa Pharmaceuticals, Ltd.
|
|
|
..................................................................................................................................................................
|
|
|
PROXY
STATEMENT |
|
|
..................................................................................................................................................................
|
|
|
Annual Meeting of Shareholders
|
|
|
June 29, 2022,
9:30 a.m. Atlantic Time (8:30 a.m. Eastern Time) |
|
| Notice of Annual Meeting of Shareholders | | | | | | | |
| | | | | 1 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | |
|
| | ||
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | |
|
| | ||
| | | | | 19 | | | |
| | | | | 19 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 28 | | | |
| | | | | 28 | | | |
| | | |
|
| | ||
| | | | | 28 | | |
| | | |
|
| |
| | | | | 34 | | | |
| | | | | 36 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 42 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 44 | | | |
| | | | | 45 | | | |
| | | |
|
| |
|
Date and Time:
|
| | Wednesday, June 29, 2022 at 9:30 a.m. Atlantic Time (8:30 a.m. Eastern Time) | |
|
Location:
|
| | Virtual meeting online at www.virtualshareholdermeeting.com/KNSA2022 | |
|
Record Date:
|
| | April 14, 2022 | |
|
Proposal
|
| |
Votes required
|
| |
Effect of votes withheld / abstentions
and broker non-votes |
|
| Proposal 1—Election of Directors | | | The plurality of the votes cast. This means that the three nominees receiving the highest number of affirmative “FOR” votes will be elected as Class I Directors. | | | Votes withheld and broker non-votes will have no effect. | |
| Proposal 2—Appointment of Auditor, delegation of authority to set Auditor remuneration, and ratification of appointment of Independent Registered Public Accounting Firm | | | The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. | | | Abstentions will have no effect. We do not expect any broker non-votes on this proposal. | |
| Proposal 3—Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers | | | The affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. | | | Abstentions and broker-non votes will have no effect. | |
|
|
| |
The Board of Directors unanimously recommends a vote FOR the election of the
Class I Director nominees listed immediately below. |
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position(s) with Kiniksa
|
|
| Sanj K. Patel | | |
52
|
| |
2015
|
| | Chief Executive Officer and Chairman of the Board | |
| Thomas R. Malley | | |
53
|
| |
2016
|
| | Director | |
| Richard S. Levy, M.D. | | |
64
|
| |
2019
|
| | Director | |
|
|
| |
SANJ K. PATEL
|
| |
Age 52
|
|
|
|
| |
THOMAS R. MALLEY
|
| |
Age 53
|
|
|
|
| |
RICHARD S. LEVY, M.D.
|
| |
Age 64
|
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position with Kiniksa
|
|
| STEPHEN R. BIGGAR, M.D., PH.D. | | |
51
|
| |
2015
|
| | Director | |
| G. BRADLEY COLE | | |
66
|
| |
2020
|
| | Director | |
| BARRY D. QUART, PHARM.D. | | |
65
|
| |
2015
|
| | Director | |
|
|
| |
STEPHEN R. BIGGAR, M.D., PH.D.
|
| |
Age 51
|
|
|
|
| |
G. BRADLEY COLE
|
| |
Age 66
|
|
|
|
| |
BARRY D. QUART PHARM.D.
|
| |
Age 65
|
|
|
Name
|
| |
Age
|
| |
Served as a
Director Since |
| |
Position with Kiniksa
|
|
| Felix J. Baker, Ph.D. | | |
53
|
| |
2015
|
| | Director | |
| Tracey L. McCain | | |
54
|
| |
2018
|
| | Director | |
| Kimberly J. Popovits | | |
63
|
| |
2018
|
| | Director | |
|
|
| |
FELIX J. BAKER, PH.D.
|
| |
Age 53
|
|
|
|
| |
TRACEY L. MCCAIN
|
| |
Age 54
|
|
|
|
| |
KIMBERLY J. POPOVITS
|
| |
Age 63
|
|
|
|
| |
The Board of Directors unanimously recommends a vote FOR the appointment of PricewaterhouseCoopers LLP as our Auditor until the close of our next Annual Meeting of Shareholders, the delegation to our Board of Directors, through our Audit Committee, of the authority to set the Auditor’s remuneration for such period, and the ratification of the appointment of PricewaterhouseCoopers LLP as our Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2022.
|
|
|
|
| |
The Board of Directors unanimously recommends a vote FOR the compensation of our named executive officers as disclosed in the Company’s proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.
|
|
|
Fee Category
|
| |
2021
|
| |
2020
|
|
| Audit Fees | | |
$971,000
|
| |
$1,111,500
|
|
| Audit-Related Fees | | |
$0
|
| |
$0
|
|
| Tax Fees | | |
$0
|
| |
$0
|
|
| All Other Fees | | |
$2,956
|
| |
$2,700
|
|
| Total Fees | | |
$973,956
|
| |
$1,114,200
|
|
| |
Board Diversity Matrix (as of April 28, 2022)
|
| | ||||||||||||||||
| |
Total Number of
Directors |
| | |
9
|
| | ||||||||||||
| | | | | | Female | | | | Male | | | | Non-Binary | | | |
Did not
Disclose Gender Identity |
| |
| | Part I: Gender Identity | | | ||||||||||||||||
| | Directors | | | |
2
|
| | |
7
|
| | |
-
|
| | |
-
|
| |
| | Part II: Demographic Diversity | | | ||||||||||||||||
| |
African American
or Black (not of Hispanic or Latinx origin) |
| | |
1
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
Alaskan Native or
Native American |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| | Asian | | | | | | | |
1
|
| | | | | | | | | |
| |
Hispanic or Latinx
|
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
Native Hawaiian
or Pacific Islander |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| |
White (not of
Hispanic or Latinx origin) |
| | |
1
|
| | |
6
|
| | |
-
|
| | |
-
|
| |
| |
Two or More
Races or Ethnicities |
| | |
-
|
| | |
-
|
| | |
-
|
| | |
-
|
| |
| | LGBTQ+ | | | |
-
|
| | ||||||||||||
| |
Did not Disclose
Demographic Background |
| | |
-
|
| |
|
Name
|
| |
Audit
|
| |
Compensation
|
| |
Nominating
and Corporate Governance |
| |
Science
and Research |
|
| Felix J. Baker, Ph.D. | | | | | |
Chair
|
| |
X
|
| |
X
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| | | | | | | |
Chair
|
| |
X
|
|
| G. Bradley Cole | | |
X
|
| | | | | | | | | |
| Richard S. Levy | | | | | | | | | | | |
Chair
|
|
| Thomas R. Malley | | |
Chair
|
| | | | |
X
|
| | | |
| Tracey McCain* | | |
X
|
| | | | | | | | | |
| Kimberly J. Popovits | | | | | |
X
|
| | | | | | |
| Barry D. Quart, Pharm.D. | | |
X
|
| |
X
|
| | | | | | |
|
Name
|
| |
Age
|
| |
Position
|
|
| Sanj K. Patel | | |
52
|
| | Chief Executive Officer and Chairman of the Board | |
| Michael Megna | | |
51
|
| |
Group Vice President, Finance and Chief Accounting Officer
|
|
| Ross Moat | | |
41
|
| | Senior Vice President and Chief Commercial Officer | |
|
John F. Paolini, M.D., Ph.D.
|
| |
57
|
| | Senior Vice President and Chief Medical Officer | |
| Mark Ragosa | | |
48
|
| | Senior Vice President and Chief Financial Officer | |
| Eben Tessari | | |
40
|
| | Senior Vice President and Chief Operating Officer | |
|
Name and principal position
|
| |
Year
|
| |
Salary
($) |
| |
Share
awards ($)(3) |
| |
Option
awards ($)(3) |
| |
Non-equity
incentive plan compensation ($) |
| |
All other
compensation ($)(4) |
| |
Total
($) |
|
|
Sanj K. Patel(1)
Chief Executive Officer and Chairman of the Board
|
| |
2021
|
| |
803,400
|
| |
1,183,978
|
| |
3,795,238
|
| |
793,962
|
| |
11,600
|
| |
6,588,178
|
|
|
2020
|
| |
780,000
|
| |
—
|
| |
3,888,414
|
| |
633,750
|
| |
11,400
|
| |
5,313,564
|
| |||
|
John F. Paolini, M.D.
Senior Vice President and Chief Medical Officer
|
| |
2021
|
| |
456,393
|
| |
321,368
|
| |
996,606
|
| |
242,863
|
| |
11,600
|
| |
2,028,830
|
|
|
Arian Pano, M.D.(2)
Senior Vice President and Chief Clinical Development Officer
|
| |
2021
|
| |
436,000
|
| |
204,677
|
| |
561,493
|
| |
158,340
|
| |
11,600
|
| |
1,372,110
|
|
|
Name
|
| |
January 1, 2021
Annual Base Salary ($) |
|
|
Sanj K. Patel
|
| |
803,400
|
|
|
John F. Paolini, M.D.
|
| |
456,393
|
|
|
Arian Pano, M.D.
|
| |
436,000
|
|
|
Named executive officer
|
| |
March 2021
share options granted |
| |
March 2021
RSUs granted |
| |
September 2021
share options granted |
| |
September 2021
RSUs granted |
|
|
Sanj K. Patel
|
| |
157,658
|
| |
26,276
|
| |
157,658
|
| |
26,276
|
|
|
John F. Paolini, M.D.
|
| |
41,400
|
| |
6,900
|
| |
41,400
|
| |
6,900
|
|
|
Arian Pano, M.D.
|
| |
23,325
|
| |
3,888
|
| |
23,325
|
| |
3,888
|
|
|
Name
|
| | | | |
Option awards(1)
|
| |
Stock awards(1)
|
| ||||||||||||||||||
|
Vesting
start date |
| |
Number of
securities underlying unexercised options (#) exercisable |
| |
Number of
securities underlying unexercised options (#) unexercisable |
| |
Option
exercise price ($) |
| |
Option
expiration date |
| |
Number of
shares or units of stock that have not vested (#) |
| |
Market
value of shares or units of stock that have not vested ($)(2) |
| | | |||||||
|
Sanj K. Patel
|
| |
8/1/2015
|
| |
325,271
|
| |
—
|
| |
1.59
|
| |
12/15/2025
|
| |
—
|
| |
—
|
| | | ||||
|
6/29/2017
|
| |
257,969
|
| |
—
|
| |
3.80
|
| |
6/28/2027
|
| |
—
|
| |
—
|
| | | |||||||
|
3/1/2018
|
| |
263,510
|
| |
175,672(3)
|
| |
10.36
|
| |
2/29/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
9/20/2018
|
| |
101,563
|
| |
23,437(4)
|
| |
30.93
|
| |
9/19/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
3/4/2019
|
| |
128,565
|
| |
58,435(4)
|
| |
17.92
|
| |
3/3/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
9/17/2019
|
| |
106,877
|
| |
83,123(4)
|
| |
8.83
|
| |
9/16/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
3/13/2020
|
| |
78,752
|
| |
101,248(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
56,251
|
| |
123,749(4)
|
| |
15.50
|
| |
9/9/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
157,658(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
26,276(5)
|
| |
309,269
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
18,555(6)
|
| |
218,392
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
12,002(7)
|
| |
141,264
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
157,658(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
26,276(5)
|
| |
309,269
|
| | | |||||||
|
John F. Paolini, M.D.
|
| |
9/14/2016
|
| |
197,574
|
| |
—
|
| |
1.86
|
| |
9/13/2026
|
| |
—
|
| |
—
|
| | | ||||
|
6/29/2017
|
| |
66,542
|
| |
—
|
| |
3.80
|
| |
6/28/2027
|
| |
—
|
| |
—
|
| | | |||||||
|
3/1/2018
|
| |
76,857
|
| |
51,237(3)
|
| |
10.36
|
| |
2/29/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
9/20/2018
|
| |
36,563
|
| |
8,437(4)
|
| |
30.93
|
| |
9/19/2028
|
| |
—
|
| |
—
|
| | | |||||||
|
3/4/2019
|
| |
35,063
|
| |
15,937(4)
|
| |
17.92
|
| |
3/3/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
9/17/2019
|
| |
25,876
|
| |
20,124(4)
|
| |
8.83
|
| |
9/16/2029
|
| |
—
|
| |
—
|
| | | |||||||
|
3/13/2020
|
| |
21,876
|
| |
28,124(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
15,626
|
| |
34,374(4)
|
| |
15.50
|
| |
9/9/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
41,400(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6,900(5)
|
| |
81,213
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5,676(6)
|
| |
66,807
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,671(7)
|
| |
43,208
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
41,400(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6,900(5)
|
| |
81,213
|
| | | |||||||
|
Arian Pano, M.D.
|
| |
12/2/2019
|
| |
52,085
|
| |
47,915(4)
|
| |
10.14
|
| |
12/1/2029
|
| |
—
|
| |
—
|
| | | ||||
|
3/13/2020
|
| |
13,126
|
| |
16,874(4)
|
| |
15.52
|
| |
3/12/2030
|
| |
—
|
| |
—
|
| | | |||||||
|
9/10/2020
|
| |
9,376
|
| |
20,624(4)
|
| |
15.50
|
| |
9/9/2020
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
23,325(4)
|
| |
22.89
|
| |
3/15/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
3/16/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,888(5)
|
| |
45,762
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
4,867(6)
|
| |
57,285
|
| | | |||||||
|
3/20/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,240(7)
|
| |
38,135
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
23,325(4)
|
| |
12.97
|
| |
9/1/2031
|
| |
—
|
| |
—
|
| | | |||||||
|
9/2/2021
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
3,888(5)
|
| |
45,762
|
| | |
|
Name
|
| |
Fees
earned or paid in cash ($) |
| |
Option
awards ($)(1) |
| |
Total ($)
|
|
|
Felix J. Baker, Ph.D.
|
| |
92,987
|
| |
297,936
|
| |
390,923
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| |
53,887
|
| |
297,936
|
| |
351,823
|
|
|
G. Bradley Cole
|
| |
49,000
|
| |
297,936
|
| |
346,936
|
|
|
Richard S. Levy, M.D.
|
| |
49,755
|
| |
297,936
|
| |
347,691
|
|
|
Thomas R. Malley
|
| |
64,000
|
| |
297,936
|
| |
361,936
|
|
|
Tracey L. McCain
|
| |
40,000
|
| |
297,936
|
| |
337,936
|
|
|
Kimberly J. Popovits
|
| |
46,300
|
| |
297,936
|
| |
344,236
|
|
|
Barry D. Quart, Pharm.D
|
| |
55,300
|
| |
297,936
|
| |
353,236
|
|
|
Name
|
| |
Option
awards(#) |
|
|
Felix J. Baker, Ph.D.
|
| |
89,517
|
|
|
Stephen R. Biggar, M.D., Ph.D.
|
| |
89,517
|
|
|
G. Bradley Cole
|
| |
71,202
|
|
|
Richard S. Levy, M.D.
|
| |
89,962
|
|
|
Thomas R. Malley
|
| |
140,293
|
|
|
Tracey L. McCain
|
| |
116,505
|
|
|
Kimberly J. Popovits
|
| |
116,505
|
|
|
Barry D. Quart, Pharm.D
|
| |
140,293
|
|
|
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights |
| |
Weighted
Average Exercise Price of Outstanding Options Warrants and Rights |
| |
Number of
Securities Available for Future Issuance Under Equity Compensation Plans(1) |
|
| Equity compensation plans approved by security holders(2) | | |
10,111,867(3)
|
| |
$14.14(4)
|
| |
4,945,891(5)
|
|
| Equity compensation plans not approved by security holders | | |
—
|
| |
—
|
| |
—
|
|
|
Total
|
| |
10,111,867
|
| |
$14.14
|
| |
4,945,891
|
|
| | | |
Class A
common shares |
| |
Class A
common shares % |
| |
Class A1
common shares |
| |
Class A1
common shares % |
| |
Class B
common shares |
| |
Class B
common shares % |
| |
Class B1
common shares |
| |
Class B1
common shares % |
| |
% of total
voting power |
|
| 5% Shareholders | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Entities Managed by Baker Bros. Advisors LP(1)
|
| |
2,978,611
|
| |
8.65%
|
| |
12,781,964
|
| |
74.62%
|
| |
—
|
| |
—
|
| |
16,057,618
|
| |
100.00%
|
| |
5.66%
|
|
|
Entities Affiliated with Hillhouse(2)
|
| |
2,920,023
|
| |
8.52%
|
| |
4,347,639
|
| |
25.38%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5.57%
|
|
|
Vanguard Group(3)
|
| |
2,890,708
|
| |
8.43%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
5.52%
|
|
| Entities affiliated with Pictet Asset Management S.A.(4) | | |
3,548,649
|
| |
10.35%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6.77%
|
|
|
Entities affiliated with Blackrock,
Inc.(5) |
| |
3,483,852
|
| |
10.17%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
6.65%
|
|
| Entities Affiliated with Dr. Robert Desnick(6) | | |
1,053,962
|
| |
3.08%
|
| |
—
|
| |
—
|
| |
214,101
|
| |
11.81%
|
| |
214,101
|
| |
1.32%
|
| |
6.10%
|
|
| Officers and Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Sanj K. Patel(7)
|
| |
1,788,834
|
| |
4.99%
|
| |
—
|
| |
—
|
| |
1,526,160
|
| |
84.16%
|
| |
1,526,160
|
| |
8.68%
|
| |
31.58%
|
|
|
John F. Paolini, M.D.(8)
|
| |
791,724
|
| |
2.26%
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
1.49%
|
|
|
Arian Pano, M.D.(9)
|
| |
155,793
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Felix J. Baker, Ph.D.(1)(10)
|
| |
3,000,771
|
| |
8.71%
|
| |
12,781,964
|
| |
74.62%
|
| |
—
|
| |
—
|
| |
16,057,618
|
| |
100.00%
|
| |
5.71%
|
|
|
Stephen R. Biggar, M.D., Ph.D.(1)
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
|
|
G. Cole Bradley(11)
|
| |
71,202
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Richard S. Levy(12)
|
| |
89,962
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Thomas R. Malley(13)
|
| |
212,260
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Tracey L. McCain(14)
|
| |
116,505
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Kimberly J. Popovits(15)
|
| |
116,505
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
Barry D. Quart, Pharm. D.(16)
|
| |
140,293
|
| |
*
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
—
|
| |
*
|
|
|
All current executive officers and directors as a group (14 persons)(17)
|
| |
7,437,477
|
| |
18.64%
|
| |
12,781,964
|
| |
74.62%
|
| |
1,526,160
|
| |
84.16%
|
| |
16,057,618
|
| |
100.00%
|
| |
40.20%
|
|